Using 3D technology to identify high-risk prostate cancer patients earlier
3D Spatial Biology of Prostate Cancer Biopsies For Earlier Identification of High Risk Patients
This study is working on a new way to help doctors find high-risk prostate cancer earlier by using advanced technology to analyze tissue samples, so they can better predict how the cancer might spread and help patients get the right treatment sooner.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Alpenglow Biosciences, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10922308 on NIH RePORTER |
What this research studies
This research focuses on improving the early detection of high-risk prostate cancer patients by utilizing a 3D spatial biology platform. The approach involves developing an automated sample preparation process and employing machine learning to analyze tissue structures from biopsy samples. By creating a predictive model, the research aims to accurately assess the risk of metastasis in patients with localized prostate cancer. This innovative technology seeks to enhance current diagnostic methods and provide timely interventions for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with localized prostate cancer who are at risk of developing metastases.
Not a fit: Patients with advanced prostate cancer that has already metastasized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier identification and treatment of high-risk prostate cancer patients, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in using 3D imaging and machine learning for cancer detection, indicating that this approach could be effective.
Where this research is happening
Seattle, United States
- Alpenglow Biosciences, INC. — Seattle, United States (Active)
Researchers
- Principal investigator: Reder, Nicholas — Alpenglow Biosciences, INC.
- Study coordinator: Reder, Nicholas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.